Marché mondial des gants 2025-2033

1. Sensibilisation croissante à la santé et à l'hygiène

2. Réglementations en matière de sécurité industrielle et sur le lieu de travail

3. Commerce électronique & Expansion du commerce de détail

4. Durabilité et innovation produit

• Gants jetables
• Gants réutilisables
• Gants chirurgicaux
• Gants d'examen
• Gants de sécurité industriels

• Nitrile
• Caoutchouc
• Vinyle
• Polyéthylène (PE)
• Néoprène et autres

• Santé et médecine
• Transformation des aliments et des boissons
• Chimie et Fabrication
• Construction et exploitation minière
• Ménage & Usage Personnel
• Applications en électronique et salles blanches

• Ventes institutionnelles directes
• Pharmacies et magasins de détail
• Plateformes en ligne / commerce électronique
• Distributeurs industriels

• Top Glove Corporation Bhd
• Hartalega Holdings Berhad
• Ansell Limited
• Kossan Rubber Industries Bhd
• Supermax Corporation Berhad
• Medline Industries, Inc.
• Cardinal Health, Inc.
• Société Kimberly-Clark
• Honeywell International Inc.
• Société 3M

• Moteur de prévision de la demande Pheonix J'ai suivi l'utilisation des gants dans les secteurs de la santé, de l'industrie et de la consommation afin d'estimer la croissance de la demande.
• Système de cartographie de la chaîne d'approvisionnement concentration notable de la fabrication de gants en Asie du Sud-Est, en particulier en Malaisie et en Thaïlande.
• Outil d’analyse des sentiments a révélé une prise de conscience croissante des consommateurs concernant les gants réutilisables et durables après 2022.
• Les cinq forces de Porter suggère un pouvoir de négociation modéré des fournisseurs (volatilité des coûts des matières premières), un pouvoir de négociation élevé des acheteurs dans les contrats en gros, et une concurrence intense entre les fabricants.

• Les gants sont essentiels pour le contrôle des infections, la sécurité industrielle et l'hygiène des consommateurs.
• L’expansion des services de santé et des politiques de sécurité au travail garantit une demande constante.
• Les matériaux durables et innovants redéfinissent la différenciation des produits.
• Les chaînes d'approvisionnement mondiales centrées en Asie offrent une production à faible coût, mais créent des opportunités de diversification.

Table des matières

• Aperçu
  1.1 Définition et périmètre du marché
  1.2 Taille du marché et prévisions (2025???2033)
  1.3 Applications clés dans divers secteurs

• Principaux moteurs de la croissance du marché
  2.1 Sensibilisation croissante à la santé et à l'hygiène
  2.2 Réglementations en matière de sécurité industrielle et sur le lieu de travail
  2.3 Expansion du commerce électronique et de la vente au détail
  2.4 Durabilité et innovation produit

• Segmentation du marché
  3.1 Par type de produit
  Gants jetables
  ??? Gants réutilisables
  Gants chirurgicaux
  Gants d'examen
  Gants de sécurité industriels
  3.2 Par matériau
  ??? Nitrile
  Dernière minute : Latex
  ??? Disque vinyle
  Polyéthylène (PE)
  Néoprène et autres
  3.3 Par Utilisation Finale
  Soins de santé et médecine
  ??? Transformation des aliments et boissons
  Produits chimiques et fabrication
  ??? Construction & Minage
  ??? Usage domestique et personnel
  Applications en électronique et salle blanche
  3.4 Par canal de distribution
  Ventes institutionnelles directes
  ??? Magasins et pharmacies de détail
  Plateformes en ligne / commerce électronique
  Distributeurs industriels

• Insights au niveau régional
  4.1 Amérique du Nord — plus grand marché (33,2 % en 2024)
  4.2 Asie-Pacifique — le marché à la croissance la plus rapide
  4.3 Europe — Croissance tirée par la réglementation et axée sur l'écologie
  4.4 Amérique latine, Moyen-Orient et Afrique — Expansion régulière

• Principales entreprises du marché
  Top Glove Corporation Bhd
  Hartalega Holdings Berhad
  Ansell Limited
  Kossan Rubber Industries Bhd
  Supermax Corporation Berhad
  Medline Industries, Inc.
  Cardinal Health, Inc.
  Société Kimberly-Clark
  Honeywell International Inc.
  ??? Société 3M

• Intelligence stratégique et perspectives basées sur l’IA
  6.1 Moteur de prévision de la demande Pheonix
  6.2 Cartographie de la chaîne d'approvisionnement — Concentration en Asie du Sud-Est
  6.3 Outil d’analyse des sentiments — Tendances de sensibilisation des consommateurs
  6.4 Analyse des cinq forces de Porter

• Aperçu des prévisions : 2025–2033
  Taille du marché 2025 : 5,96 milliards USD
  Taille du marché en 2033 : ~11,2 milliards USD
  TCAC ??? (2025???2033) : ~8,5 %
  Région la plus importante (2024) : Amérique du Nord (33,2 %)
  Région à la croissance la plus rapide : Asie-Pacifique
  Segment supérieur : gants jetables en nitrile
  ??? Tendances clés : Innovations écologiques et hypoallergéniques
  ??? Axe de croissance futur : matériaux durables, automatisation, demande dans le secteur de la santé

• Pourquoi le marché mondial reste crucial
  Indispensable pour la santé, la sécurité industrielle et l'hygiène des consommateurs.
  L'expansion des réglementations en matière de soins de santé et de sécurité stimule l'adoption
  L'innovation dans les matériaux durables et sans allergènes crée des opportunités
  Points forts de la chaîne d'approvisionnement mondiale et perspectives de diversification

• Conclusion

Paysage concurrentiel

This industry does not have one competitive landscape. It has four, stacked, and they barely bid against each other. Getting this wrong is the most common analytical error in the sector, because it produces the claim that the market is “highly consolidated” on the strength of a Malaysian top four that in fact controls nothing globally.

Layer one: the Malaysian contract manufacturers

Top Glove, Hartalega, Kossan, Supermax and Riverstone sell capacity, not brands. Their customers are distributors, hospital group purchasing organisations and the brand owners above them, and the product is specified to a standard rather than to a name. This layer is where the industry’s cost debate actually lives, and the debate is internal: Top Glove’s cost of goods near USD 17.50 per 1,000 pieces against Hartalega’s near USD 22.00 is a 26 per cent spread between two plants making the same product for the same customers. That spread is scale, automation, energy contract and product mix, in roughly that order. It is also why the Malaysian industry’s problem is not primarily Chinese: a Malaysian plant at Hartalega’s cost base is already uncompetitive with a Malaysian plant at Top Glove’s.

Their financials show what a commodity with no pricing power looks like at the bottom of a cycle. Hartalega’s FY2026, the year to 31 March 2026, produced revenue of RM2,135 million, profit before tax of RM117 million and profit after tax of RM102 million — a 5.5 per cent pre-tax margin and 4.8 per cent net. Top Glove’s nine months to 31 May 2026 produced revenue of RM2,984 million, up 15 per cent year on year, on sales volume up 34 per cent, with an EBITDA margin of 15 per cent. Volume up a third and revenue up a seventh tells you precisely where the price went.

Layer two: the Chinese volume producers

Intco Medical and Blue Sail are the two names that matter, and they have done what Chinese manufacturers do: built modern, highly automated lines at a domestic energy cost Malaysian producers cannot match, and priced at USD 13 to 15 per 1,000 pieces. The share numbers are stark. China held about 11 per cent of global glove supply in 2019 and about 34 per cent in 2025; Malaysia went from 63 per cent to roughly 35 per cent over the same period. Neither movement was driven by product quality. Both were driven by unit cost.

What is unusual here is that the Chinese build continued into an oversupplied market. That is not irrationality; it is a bet that the marginal producer in Malaysia will exit first, because Malaysian plants carry ringgit-denominated debt, gas take-or-pay obligations and older assets. So far the bet has paid.

Layer three: the brand and channel owners

Ansell, Cardinal Health, Medline, Kimberly-Clark and McKesson own the specification and the customer relationship, and increasingly own less of the manufacturing. They buy from layers one and two, add the regulatory file and the logistics, and sell to hospitals at a 15 to 25 per cent margin over the factory gate. This layer is the only genuinely consolidated one, and it is where the pricing power sits in a shortage: in 2020 and 2021 the brand owners earned more per glove than the manufacturers did, because they held the contracts and the allocation.

The strategic consequence for anyone modelling this market is that the factory gate price and the hospital price move differently. A 100 per cent tariff on Chinese medical gloves is paid at the border by the importer — normally a layer-three firm — and whether it reaches the consumer depends on the contract. In 2026 the answer is that it partly did: distributors passed through most of the duty on exam gloves because every alternative source was also tariffed or short.

Layer four: the qualified specialists

Surgical gloves, chemotherapy-tested gloves (ASTM D6978), cleanroom-compatible and accelerator-free formulations sit in a fourth layer where qualification, not cost, decides. A sterile surgical glove requires a validated sterilisation process, a biocompatibility file and, in Europe, notified-body involvement; a chemotherapy glove requires permeation testing against a defined panel of cytotoxics. These are the only segments in the market where a producer can hold price through a downturn, and they are why the surgical line in this report grows at 7.02 per cent against 6.75 per cent for nitrile examination.

So how concentrated is it, really?

No producer holds more than about a fifth of world capacity, and the top six hold somewhere between 35 and 45 per cent of it depending on whether capacity or actual output is counted — a range, because the manufacturers do not publish comparable utilisation. That is moderate concentration on any definition, and it is the number used in this report. Malaysia’s four largest producers are concentrated relative to Malaysia, not relative to the market.

The measurement problem underneath is worse than the concentration question. Pieces, value, capacity and output give four different rankings, and the industry quotes whichever one flatters it. A firm can be third by capacity, eighth by output and twelfth by revenue in the same year. Any share claim in this sector that does not state its denominator is not a share claim.

What the next eight years do to this structure

Two forces. The tariff wedge, if it holds, protects the American book and lets Malaysian producers earn a normal return on the 46 per cent of exports that go there while shrinking in the rest of the world. And Chinese cost leadership, unopposed outside the United States, keeps compressing the price of the 54 per cent that does not. The result is not consolidation. It is a slow bifurcation: a tariff-protected, higher-cost, compliance-heavy supply base serving North America, and a Chinese supply base serving everyone else at a price the Americans are not allowed to buy.

Chaîne de valeur

The glove value chain is a chemical conversion business wearing a commodity’s clothes. Six links separate butadiene from a sterile pack, and the margin in each is set by a different constraint. Only one of them is the polymer, and it is not the one that decides quality.

Link one: the feedstock nobody models

Nitrile examination gloves are made from nitrile butadiene rubber latex, a copolymer of butadiene and acrylonitrile supplied by a small group of specialist producers — Synthomer, Zeon and LG Chem are the three that matter — with a handful of regional suppliers behind them. This is the most concentrated link in the chain, and it is the one with the shortest fuse.

In the first quarter of 2026 the fuse lit. Nitrile latex costs rose 36 per cent in a single quarter at Top Glove, driven by shipping disruption that ran through the Strait of Hormuz into butadiene-linked feedstock, while natural rubber latex concentrate rose 12 per cent. The manufacturers’ association asked the Malaysian government for temporary relief from gas take-or-pay obligations and for domestic NBR allocation. Raw material is 30 to 40 per cent of a glove’s cost, so a 36 per cent move in latex is a 12 to 14 per cent move in total cost — larger than the entire net margin of most producers in the industry.

Natural rubber latex, the second feedstock, is a smallholder crop concentrated in Thailand, Vietnam and Côte d’Ivoire and priced off ribbed smoked sheet. It is seasonal, weather-driven and has no supply-chain concentration problem — which is exactly why the accelerated shift to nitrile over the past fifteen years was driven by cost and allergy, not by security of supply. The 2026 shock reversed that logic for a quarter.

Link two: compounding, where the allergens live

Latex is compounded with sulphur, accelerators (thiurams, dithiocarbamates, benzothiazoles), activators such as zinc oxide, and antioxidants. This is where the two allergy problems originate. Type I latex allergy is a protein response and was engineered down by leaching and chlorination; Type IV contact dermatitis is a chemical response to residual accelerators and is still the live regulatory issue in Europe. The formulatory answer — dithiocarbamate-free and thiuram-free cure systems — costs 3 to 8 per cent more per glove and produces a slightly worse tensile profile. That trade is the whole of the segment’s product innovation, and it is worth stating plainly: there has been no fundamental chemistry change in this industry in two decades.

Link three: the dip, and the hinge that is not the polymer

A former — a ceramic hand-shaped mandrel, one per glove size — is cleaned, dipped in coagulant, dipped in latex, gelled, leached, cured in a tunnel at 100 to 140 degrees Celsius, then stripped. A modern line runs 30,000 to 45,000 pieces an hour and roughly a million pieces a day. The capital cost of a line is small relative to most process industries; the operating cost is not.

The hinge is the leaching step. Water extraction after gelling removes residual proteins, residual accelerators and ionic contaminants, and it sets the pinhole rate, the tensile strength after ageing, and the extractables that determine whether a glove passes a pharmacopoeial or a chemotherapy-permeation test. It is also the most water- and energy-intensive step in the plant. That is why a gas price is a glove cost, why Malaysia’s manufacturers asked for take-or-pay relief rather than a subsidy, and why the highest-quality producers are distinguished not by their polymer but by their water treatment and their tunnel control.

Link four: test, sterilise, pack

Every batch is sampled for watertightness under an acceptance quality limit, typically 1.5, and tested for tensile strength before and after accelerated ageing. Surgical gloves then go through ethylene oxide or gamma sterilisation, aeration to drive off residuals, and packaging validated to ISO 11607. This link is where a commodity becomes a medical device, and it is the reason qualification is the real barrier to entry rather than capital: a line costs a few million dollars and nine to twelve months, while getting onto a hospital formulary or a national framework agreement costs eighteen to thirty-six months and a regulatory file.

Link five: the channel

Between the factory and the ward sits a distributor that holds stock, carries the regulatory registration in its own jurisdiction, and takes the working capital risk. In the United States that layer earns 15 to 25 per cent over the factory gate; in Europe it is thinner because national procurement is more concentrated. The channel is also where tariffs are actually paid, which means the channel — not the manufacturer — decides how much of a duty reaches the hospital.

Where the margin goes, stated as a rule

In a shortage, upstream captures and downstream absorbs. The 2026 quarter proves it arithmetically: average selling prices rose 17 per cent while nitrile latex cost rose 36 per cent. The glovemaker passed on less than half its input inflation in the same quarter, and did so while running at high utilisation. That is what a price-taking converter looks like, and it is the single most useful fact in this chapter: no link in this chain except the latex supplier has the power to set a price rather than accept one.

The corollary is that vertical integration upstream is worth more than integration downstream. A producer with an ownership stake in latex supply has a structurally different cost curve from one buying on contract, and that difference — not automation, not brand — is the only durable margin advantage available in the industry.

Activité d'investissement

Almost nobody is building a glove plant to make gloves. The capital going into this industry is going into automation, product mix and energy, in that order, and the reason is a return calculation that does not work at current prices.

The arithmetic that stops a greenfield build

A dipping line producing 45,000 pieces an hour costs a few million dollars and takes nine to twelve months to install. At an examination glove price of USD 20 per 1,000 pieces, a line running flat out for a year produces about 394 million pieces and roughly USD 7.9 million of revenue. Chinese producers sell at USD 13 to 15 per 1,000, which puts the same line’s output at USD 5.1 to 5.9 million of revenue. A Malaysian producer whose cost of goods is USD 17.50 to USD 22.00 per 1,000 is therefore at or above the selling price of its lowest-cost competitor before a single dollar of capital is recovered. No amount of engineering solves that. Only a tariff, a mix shift or a feedstock advantage does.

This is why the Malaysian industry retired capacity through 2023 to 2025 instead of adding it: older, less efficient lines were phased out rather than replaced one-for-one, and the volume that remained moved onto the better assets. It is capacity exit disguised as maintenance.

What the Chinese build is actually funded by

The expansion that took China from 11 to about 34 per cent of global supply was funded on a different cost base — cheaper energy, newer assets, domestic capital that does not demand a cyclical return — and it continued into oversupply deliberately. The strategic logic is that the highest-cost producer exits first, and the highest-cost producer is a Malaysian plant with ringgit debt and gas take-or-pay commitments. Investors who treat the Chinese build as a misallocation are reading it as a market when it is being run as a strategic industry.

The balance sheets that would have to fund it

The Malaysian producers came out of the 2021 boom with repaired balance sheets. Top Glove reported net gearing of 0.01 times at the end of its third quarter of FY2026, positive operating cash flow and continued repayment of borrowings. Hartalega earned RM102 million of profit after tax on RM2,135 million of revenue in FY2026 — a 4.8 per cent net margin, which on that revenue funds something like RM100 to 150 million a year of capital expenditure at most.

That is enough to automate and to shift mix. It is not enough to out-build a competitor with a lower cost base and cheaper capital. So the capital that is being deployed goes where the return is defensible: strip-and-stack robotics to take labour out of the line, vision inspection to move from sampled to full inspection, dedicated lines for chemotherapy-tested and cleanroom products, and energy projects — biomass, cogeneration, heat recovery — that attack the gas line rather than the polymer line.

Consolidation that has not happened

This is the sector where consolidation is most obviously rational and least likely. The assets are cheap, the industry is fragmented at the top, and the cost spread between the best and worst operators is 26 per cent — precisely the conditions that usually produce a roll-up. It has not produced one, for two reasons. The Malaysian producers are family-controlled and were briefly, in 2021, among the most profitable companies in the country, which makes sellers expensive in expectation even when the assets are cheap in fact. And the buyers who could afford to consolidate — the layer-three brand owners — have spent the last decade moving in the opposite direction, towards asset-light sourcing.

What we are not going to pretend to know

There is no published capital expenditure series that isolates glove manufacturing. The Malaysian producers report capex inside a consolidated cash flow statement, the Chinese producers report in a different accounting framework, and no trade body publishes an industry aggregate. This chapter therefore gives direction and magnitude per line, and refuses to invent a market-level investment figure. What can be said with confidence is that the investment trend is flat to marginally positive, that it is directed at cost and compliance rather than at volume, and that no new producing country of scale has emerged in the past five years.

The one thing that would change the trend is a durable tariff wall. If the American market were permanently closed to Chinese gloves while remaining open to Malaysian ones, the return on a Malaysian line changes materially at the same cost of goods — and the industry’s first genuinely capacity-adding investment cycle since 2021 would follow within eighteen months. That is the bet to watch, and it is a policy bet, not an engineering one.

Technologie et innovation

The molecule has no roadmap. There is no next-generation nitrile waiting to displace the current one, no barrier material that beats a film of cross-linked rubber on cost and performance at scale, and no sterilisation technology that removes the need for the physical glove. What innovation exists in this industry is process economics and compliance engineering, and both are measured in fractions of a cent per glove rather than in new products.

Thin-wall: the only product innovation that changes the cost line

Examination gloves have gone from roughly 0.06 millimetres to 0.03 to 0.04 millimetres at the finger in fifteen years, and because the glove is sold by the piece rather than by weight, every micron removed is material the producer does not buy. A move from 0.06 to 0.04 millimetres takes close to a third out of the latex consumed per glove, which on a 30 to 40 per cent raw-material share of cost is worth more than a decade of energy efficiency work.

The constraint is not the polymer science; it is the acceptance quality limit. Pinholes rise as the wall thins, and the standard permits an AQL of 1.5 on watertightness — a sampling regime that tolerates defects in a sample in order to accept a batch. Thinner film also loses tensile strength after accelerated ageing, which is tested before and after. So the frontier is a manufacturing frontier: how thin a glove can be made while holding the pinhole rate and the aged tensile together, at 45,000 pieces an hour, on a former that is wearing.

Inspection: where automation is real rather than marketed

The most consequential technology in a modern glove plant is machine vision, and it is consequential precisely because it replaces a sampling regime with an inspection one. In-line camera systems look for holes, contamination, colour variation and former marks on every piece at line speed, and they are the reason a producer can defend a thin-wall claim at all. The commercial effect is not cosmetic: an inspector finding one defect in a sample of 80 tells you the batch may be acceptable, whereas a camera finding one defect in 45,000 pieces tells you the line is drifting, in time to correct it.

Behind that sits strip-and-stack robotics, which took six to ten operators out of a line and is now standard on new capacity rather than a differentiator; and above it sits line-level manufacturing execution software that ties former identity to batch records. That last link is what makes a recall survivable, and it is increasingly what a hospital group’s audit asks to see.

Chemistry: allergic disease as an engineering constraint

Two chemistries matter and neither is new. Type I latex allergy, a protein response, was engineered down by leaching and chlorination and is now a minor issue in mature markets. Type IV contact dermatitis, a response to residual accelerators, is the live one: dithiocarbamate-free and thiuram-free cure systems exist, cost 3 to 8 per cent more per glove, and produce a slightly weaker tensile profile that has to be designed around. This is the entirety of the segment’s chemistry innovation, and it is driven by European dermatology practice rather than by any product ambition.

The adjacent development with real commercial value is permeation testing to ASTM D6978 for chemotherapy drugs, which is a formulation and process problem rather than a new material: thickness, cross-link density and the absence of polar additives all matter. Passing it moves a glove from USD 20 per 1,000 to a multiple of that, which is why the surgical and speciality lines grow faster than the commodity one.

Energy, water and the sustainability claims worth believing

Curing runs at 100 to 140 degrees Celsius in a gas-fired tunnel, and gas is 8 to 12 per cent of unit cost. The engineering responses are unglamorous: heat recovery from the tunnel exhaust, cogeneration, and in Malaysia a shift towards biomass and biogas where the site allows it. Leaching is the water problem, and closed-loop treatment with reverse osmosis is now standard at the better plants because the same water quality that satisfies an environmental permit also satisfies a customer audit.

On materials, the honest position is that there is no commercially proven biodegradable nitrile at scale. Bio-attributed nitrile via mass balance exists and sells at a premium into European tenders; it changes the feedstock accounting, not the end-of-life behaviour of the glove. The credible environmental lever in this industry is material efficiency — the thin-wall curve above — because it reduces cost and footprint on the same axis. Any claim that a glove is compostable should be read as a claim about a specific test condition, not about a hospital’s waste stream.

Why patent activity is low and will stay low

Patent filings in this sector are thin, and the reason is structural: the inventions are process settings, former geometry and compound recipes, all of which are better protected by secrecy and by the difficulty of transferring tacit knowledge to a new line than by a published claim. The defensible assets are a validated file, a customer qualification and a cost base. That is why this report scores innovation intensity as moderate, patent activity as low and technology maturity as mature — three judgements that describe an industry where the technology race was run and settled, and the competition moved to cost, compliance and trade policy.

Risque de marché

Six risks sit on this market. One of them is dominant, it is live, and it is not a market risk at all — it is a legal one. The others are ranked below it because none of them can move the number by a quarter on their own.

1. Trade policy — dominant

The American duty stack on medical gloves is now the single largest determinant of this market’s value, and it is being litigated and re-drafted in three separate places at once. Section 301 on HTS 4015.12.10 moved to 100 per cent on 1 January 2026. A Section 232 investigation into most medical products, opened in autumn 2025, must be completed by 30 May 2026. And the legality of the IEEPA tariffs sits before the Supreme Court in Learning Resources v. Trump, with refund suits paused by the Court of International Trade pending that ruling.

The exposure is concentrated: the United States takes 46 per cent of Malaysia’s glove exports. If the wedge narrows — whether by a Supreme Court ruling against the IEEPA layer or by a 232 outcome that taxes Malaysia too — the conservative path in this report is what the market looks like, and it is 25.2 per cent below the baseline by 2033. The upside case is 16.2 per cent above. That asymmetry is the honest shape of the risk: policy can take more away than it has already given.

2. Nitrile latex supply — high

Raw material is 30 to 40 per cent of unit cost and comes from three specialist suppliers. In the first quarter of 2026 latex costs rose 36 per cent in a single quarter while selling prices rose 17 per cent, which means the entire shock was absorbed. A repeat that lasts four quarters rather than one would not be absorbed; it would close marginal producers. The associated exposure is contractual: gas take-or-pay obligations mean a Malaysian plant pays for energy it does not consume when utilisation falls, which is precisely what happened when the industry asked for relief in March 2026.

3. Chronic overcapacity — high

The Chinese build continued into oversupply. That is the mechanism by which the 54 per cent of Malaysian exports that face no tariff wall keep losing price. Volume in this market grows 4.2 per cent a year; announced capacity has grown faster than that for five years. Overcapacity in this industry does not express itself as idle plants — it expresses itself as price, because a dipping line has low shutdown and restart costs and producers run to cover fixed energy commitments.

4. Customer and geographic concentration — moderate

Malaysia ships 46 per cent to the United States, 21 per cent to the European Union, 6 per cent to Japan and 4 per cent to China, with the remainder spread over more than 160 countries. No single customer is decisive, but a single market is, and that market’s tariff policy is being rewritten in real time. At the manufacturer level the concentration is worse than the trade data suggests: a handful of layer-three brand owners and group purchasing organisations control the majority of hospital volume in the United States and Europe.

5. Compliance failure — moderate, and under-priced

This is the risk management teams discount and procurement teams do not. A failed notified-body audit, a withdrawn certificate, a customs detention or a regulator’s import alert ends a customer relationship for years rather than quarters, and the product is cheap enough that a hospital will switch rather than wait. The 2026 environment — where a single tariff line can double a landed cost — makes origin and documentation errors more likely, not less.

6. Energy cost and single-use pressure — moderate

Gas is 8 to 12 per cent of cost, and the curing tunnel cannot run on anything else without capex. Separately, the demand-side risk for the non-medical single-use segment is real: hotels, restaurants and beauty salons are the categories where single-use reduction policy actually bites, and that segment is 13 per cent of 2025 value and grows fastest in this forecast. The medical segments do not face that pressure in any jurisdiction — no regulator is restricting examination gloves, and none is likely to.

What is not on this list, and why

Technology substitution is not a material risk in an eight-year window. There is no polymer on the horizon that beats nitrile on cost and barrier at scale, and no sterilisation method that removes the need for a physical barrier. Nor is demand collapse: the per-capita gap between 5 to 10 pieces in most of Asia and 250 in the United States is the most reliable growth engine in the whole medical consumables complex.

The composite risk view this report takes is: overall moderate, geopolitical high, substitution low — with the caveat that “moderate” is doing a lot of work, because the distribution around the baseline is unusually wide and unusually policy-driven.

Paysage réglementaire

Two regulators decide whether a glove may be sold at all, and a third decides at what price. The two are the United States Food and Drug Administration and the European Commission; the third is the United States Trade Representative. Conflating them is a common error in this sector, and it is why producers who hold every certificate can still be priced out of a market overnight.

Classification: two regimes, two logics

In the United States, surgeon’s gloves fall under 21 CFR 878.4460 as Class II devices requiring a 510(k) premarket notification, while patient examination gloves fall under 21 CFR 880.6250 as Class I devices exempt from 510(k) but still bound by the quality system regulation, by consensus standards and by establishment registration. In the European Union, examination gloves are Class I under the Medical Device Regulation 2017/745 and become Class Is — requiring notified-body involvement — the moment they are sterile; surgical gloves classify as Class IIa by virtue of being transiently surgically invasive.

The practical consequence is that a sterile surgical glove carries a conformity assessment burden that an examination glove does not, and that is why the surgical segment behaves differently commercially. It is also why qualification, not capital, is the real barrier to entry: the notified-body queue is the binding constraint on new supply, and it does not clear quickly.

The standards that carry the commercial weight

EN 455 parts 1 to 4 govern watertightness, physical properties, biological evaluation and shelf life for medical gloves in Europe; ASTM D3578 and D6319 do the equivalent for latex and nitrile examination gloves in the United States, with D3577 and D7160 covering surgical gloves. Two more standards matter disproportionately to value. ASTM D6978 governs resistance to permeation by chemotherapy drugs, and passing it is what allows a producer to sell into oncology at a multiple of the examination glove price. ASTM F1671 governs resistance to penetration by bloodborne pathogens and is a gate for high-risk surgical and emergency use.

For non-medical products the governing instrument is different in kind: the EU Personal Protective Equipment Regulation 2016/425, with the EN ISO 374 series defining chemical protection categories and requiring type-examination by a notified body. A producer selling the same physical glove into a hospital and a factory is answering to two different regulators with two different files, which is exactly why the non-medical segment has a thinner, more distributor-led supply base.

Market surveillance, and what actually happens when it fails

Post-market obligations are where certificates are lost. Under MDR a manufacturer carries a vigilance system, unique device identification and periodic safety reporting; in the United States the equivalent is medical device reporting plus the FDA’s inspection and import-alert machinery. Both regimes allow a regulator to stop product at the border without a recall, and in a market where the product is a commodity, a detained shipment is a lost customer rather than a delay.

Malaysia adds a third layer for anything sold domestically — registration under the Medical Device Act 2012 — but the industry is overwhelmingly export-oriented, which means its plants carry FDA registration, MDR conformity and, increasingly, MDSAP certification simultaneously. Compliance cost is therefore largely fixed per site, which favours scale: the smallest producers pay the same notified-body fees as the largest.

Tariff as a regulatory process, with a clock

Three dated proceedings belong in a regulatory chapter rather than a commercial one, because each is a legal process with a statutory timetable and a defined output.

Section 232. The Department of Commerce investigation into most medical products, opened in autumn 2025, must conclude by 30 May 2026. A positive determination permits the President to impose duties on national security grounds, and unlike Section 301 those duties need not be country-specific — which is the point of interest here, since an affirmative finding could reach Malaysian supply.

The IEEPA litigation. Learning Resources v. Trump was argued in November 2025 with a decision expected in early 2026, and the Court of International Trade paused refund litigation on 23 December 2025 pending the outcome. A ruling against the IEEPA layer affects the reciprocal component of the duty stack, not Section 301.

USMCA. The formal review begins in July 2026, and the administration has indicated it does not intend a straightforward extension. The relevance to gloves is indirect but real: near-shoring to Mexico becomes materially more attractive to American buyers if the agreement is renegotiated in a way that protects North American production.

One thing that is not a regulatory risk, despite the reporting

The EU Packaging and Packaging Waste Regulation does not reach medical gloves — it governs packaging, and the glove is the product. Nor is there any jurisdiction restricting single-use examination or surgical gloves on environmental grounds, for the obvious reason that an alternative does not exist. The environmental pressure in this sector is real but it operates through procurement criteria and disclosure requirements on manufacturers, not through product restriction. A forecast that assumes a regulatory constraint on single-use medical gloves within this window is assuming something that has not been proposed, let alone adopted.